Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients

Transplant Infectious Disease

Volumn 15, Issue 5, 2013, Pages 493-501

  Krishna, S G ^a,b   Zhao, W ^a   Apewokin, S K ^a   Krishna, K ^a   Chepyala, P ^a   Anaissie, E J ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Anti motility drugs; Antiperistaltic drugs; Chemotherapy; Clostridium difficile; Loperamide; Lower alimentary tract mucositis; Multiple myeloma; Stem cell transplantation

Indexed keywords

ACICLOVIR; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; LEVOFLOXACIN; LOPERAMIDE; MELPHALAN; METRONIDAZOLE; THALIDOMIDE; VANCOMYCIN; ANTIDIARRHEAL AGENT;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CLOSTRIDIUM DIFFICILE INFECTION; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; TREATMENT DURATION; ADVERSE EFFECTS; CLOSTRIDIUM INFECTIONS; COMPLICATION; CONTRAINDICATIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; ISOLATION AND PURIFICATION; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; RISK; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; ANTIDIARRHEALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LOGISTIC MODELS; LOPERAMIDE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; ODDS RATIO; RISK FACTORS; TREATMENT OUTCOME;

EID: 84884981727     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12112     Document Type: Article

References (41)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31 (5): 431-455.
2. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30 (1): 57-66.
3. Gorschluter M, Glasmacher A, Hahn C, et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001; 33 (6): 786-791.
4. Chopra T, Chandrasekar P, Salimnia H, Heilbrun LK, Smith D, Alangaden GJ. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 2011; 25 (1): E82-E87.
5. Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant 2000; 26 (8): 871-876.
6. Vehreschild MJ, Meissner AM, Cornely OA, et al. Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. Haematologica 2011; 96 (12): 1855-1860.
7. Avery R, Pohlman B, Adal K, et al. High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients. Bone Marrow Transplant 2000; 25 (1): 67-69.
8. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24 (3): 324-333.
9. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170 (9): 772-778.
10. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365 (18): 1693-1703.
11. Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005; 6 (2): 105-108.
12. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45 (12): 1543-1549.
13. Anthony DM, Reynolds T, Paton J, Rafter L. Serum albumin in risk assessment for Clostridium difficile. J Hosp Infect 2009; 71 (4): 378-379.
14. Yousuf K, Saklayen MG, Markert RJ, Barde CJ, Gopalswamy N. Clostridium difficile-associated diarrhea and chronic renal insufficiency. South Med J 2002; 95 (7): 681-683.
15. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009; 136 (4): 1206-1214.
16. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342 (6): 390-397.
17. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118 (4 Pt 1): 633-637.
18. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40 (11): 1591-1597.
19. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362 (3): 197-205.
20. Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009; 48 (5): 598-605.
21. Krishna SG, Zhao W, Grazziutti ML, Sanathkumar N, Barlogie B, Anaissie EJ. Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer 2011; 117 (3): 648-655.
22. Khan SA, Wingard JR. Infection and mucosal injury in cancer treatment. J Natl Cancer Inst Monogr 2001; 29: 31-36.
23. Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 2003; 98 (11): 2363-2371.
24. Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010; 115 (21): 4168-4173.
25. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353 (10): 977-987.
26. NCI. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at http://ctep.cancer.gov/reporting/ctc_v30.html (August 9, 2006).
27. Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22 (14): 2918-2926.
28. Grazziutti ML, Dong L, Miceli MH, et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006; 38 (7): 501-506.
29. Gerding DN. Antimotility agents for the treatment of Clostridium difficile infection: is the juice worth the squeeze? Clin Infect Dis 2009; 48 (5): 606-608.
30. Dudukgian H, Sie E, Gonzalez-Ruiz C, Etzioni DA, Kaiser AM. C. difficile colitis-predictors of fatal outcome. J Gastrointest Surg 2010; 14 (2): 315-322.
31. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235 (3): 363-372.
32. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26 (3): 273-280.
33. Synnott K, Mealy K, Merry C, Kyne L, Keane C, Quill R. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg 1998; 85 (2): 229-231.
34. Raveh D, Rabinowitz B, Breuer GS, Rudensky B, Yinnon AM. Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea. Int J Antimicrob Agents 2006; 28 (3): 231-237.
35. Pant C, Madonia PN, Jordan P, Manas K, Bass P 3rd. Harbingers for Clostridium difficile-associated diarrhea. J Investig Med 2009; 57 (1): 40-42.
36. Sheth H, Bernardini J, Burr R, et al. Clostridium difficile infections in outpatient dialysis cohort. Infect Control Hosp Epidemiol 2010; 31 (1): 89-91.
37. Ramaswamy R, Grover H, Corpuz M, Daniels P, Pitchumoni CS. Prognostic criteria in Clostridium difficile colitis. Am J Gastroenterol 1996; 91 (3): 460-464.
38. Anaissie E, Mink T. The cancer supportive care model: a patient-partnered paradigm shift in health care delivery. J Participat Med 2011; 2: e26.
39. Cadena J, Thompson GR 3rd, Patterson JE, et al. Clinical predictors and risk factors for relapsing Clostridium difficile infection. Am J Med Sci 2010; 339 (4): 350-355.
40. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78 (1): 21-33.
41. Yoo EM, Chintalacharuvu KR, Penichet ML, Morrison SL. Myeloma expression systems. J Immunol Methods 2002; 2 (1-2): 1-20.